Imatinib and Trametinib for KRAS-mutated solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have an advanced solid tumor with a KRAS G12X mutation that has gotten worse during or within 6 months of standard chemotherapy, or no standard therapy exists.
- Your tumor can be measured on scans (using RECIST criteria).
- You are able to perform daily activities with some help (ECOG score 0-2) and have a life expectancy of at least 8 weeks.
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges.
- You have not had an allergic reaction to imatinib or trametinib, and you are not currently taking other kinase inhibitors or strong interacting medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
This trial tests a combination of three drugs (trametinib, anlotinib, and tislelizumab) for people with KRAS-mutant non-small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.